Globus Medical Slides After Full-Year Revenue Guidance Held Steady

Dow Jones

05/09

By Christopher Kuo

Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue.

The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date.

The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion.

The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said.

Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said.

The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier.

Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share.

Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million.

The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share.

(MORE TO FOLLOW) Dow Jones Newswires

May 08, 2026 15:11 ET (19:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2634461836"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634461836\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634461836?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 03:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634461836","market":"other","top_or_hot":-1,"title":"Globus Medical Slides After Full-Year Revenue Guidance Held Steady","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n</p>\n<p>\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n</p>\n<p>\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n</p>\n<p>\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n</p>\n<p>\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n</p>\n<p>\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n</p>\n<p>\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n</p>\n<p>\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:11 ET (19:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Globus Medical Slides After Full-Year Revenue Guidance Held Steady</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobus Medical Slides After Full-Year Revenue Guidance Held Steady\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-09 03:11</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n</p>\n<p>\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n</p>\n<p>\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n</p>\n<p>\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n</p>\n<p>\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n</p>\n<p>\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n</p>\n<p>\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n</p>\n<p>\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:11 ET (19:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMED","symbol_name":"Globus Medical Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634461836","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634461836","pubTimestamp":1778267460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue.The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date.The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion.The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said.Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said.The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier.Adjusted earnings came in at $1.12 a share. Analysts polled by FactSe","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GMED":"Globus Medical Inc"},"translate_title":"Globus Medical在全年收入指引保持稳定后下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMED":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Shares of Globus Medical fell after the musculoskeletal medical device company reaffirmed its guidance for full-year revenue. \n\n\n  The stock declined 8.3%, to $78.03, Friday afternoon and is down 11% year to date. \n\n\n  The company on Thursday backed its full-year guidance for revenue, projecting $3.18 billion to $3.22 billion. Analysts polled by FactSet expect $3.2 billion. \n\n\n  The company didn't raise the full-year guidance for revenue in part because of strategy changes at its Enabling Technology division and continuing revenue challenges with its Nevro business, Chief Executive Keith Pfeil said. \n\n\n  Revenue contribution from the company's Nevro business declined 17% from the fourth quarter of 2025, due to structural changes made in sales and marketing, Chief Financial Officer Kyle Kline said. \n\n\n  The company posted a first-quarter profit of $124.3 million, or 90 cents a share, compared with $75.5 million, or 54 cents a share, a year earlier. \n\n\n  Adjusted earnings came in at $1.12 a share. Analysts polled by FactSet expected 92 cents a share. \n\n\n  Revenue rose to $759.9 million from $598.1 million. Analysts expected $740.3 million. \n\n\n  The company raised its full-year guidance for adjusted earnings per share to $4.70 to $4.80, up from previous guidance of $4.40 to $4.50. Analysts expect $4.67 a share. \n\n\n \n\n\n  (MORE TO FOLLOW) Dow Jones Newswires\n\n\n  May 08, 2026 15:11 ET (19:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}